Your session is about to expire
← Back to Search
Virus Therapy
HIV Vaccine for Human Immunodeficiency Virus Infection
Phase 1
Waitlist Available
Led By Marina Caskey, MD
Research Sponsored by International AIDS Vaccine Initiative
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 18 months
Awards & highlights
Study Summary
This trial is testing a new HIV vaccine to see if it is safe and causes an immune response.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 18 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~18 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Safety - Grade 2 or greater unsolicited AEs
Safety - IP related SAEs
Safety - IP related unsolicited adverse events
+2 moreSecondary outcome measures
Immunogenicity - Frequency Ab responses
Immunogenicity - Magnitude Ab responses
Trial Design
2Treatment groups
Experimental Treatment
Group I: Investigational Product, 300 µg/ PlaceboExperimental Treatment2 Interventions
300 µg IM, months 0, 2 and 6
Group II: Investigational Product, 30 µg/ PlaceboExperimental Treatment2 Interventions
30 µg IM, months 0, 2 and 6
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
International AIDS Vaccine InitiativeLead Sponsor
48 Previous Clinical Trials
13,212 Total Patients Enrolled
George Washington UniversityOTHER
243 Previous Clinical Trials
453,199 Total Patients Enrolled
Rockefeller UniversityOTHER
159 Previous Clinical Trials
16,459 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:Research Study Groups:
This trial has the following groups:- Group 1: Investigational Product, 300 µg/ Placebo
- Group 2: Investigational Product, 30 µg/ Placebo
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger